Paxton Major
Director at Northpond Ventures
Cambridge, Massachusetts
Overview
Work Experience
Managing Director
2018 - Current
Northpond Ventures is a science-driven venture capital firm founded with a mission to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries. The firm has over $2 billion in committed capital and offices in Cambridge, MA; San Francisco, CA; and Bethesda, MD.
Northpond Ventures is a private equity and venture capital that focuses on science-driven projects in life sciences and technology.
Board Director
2024
Enzymatic RNA synthesis
EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
Raised $12,000,000.00 from Coatue, Breakout Ventures and Northpond Ventures.
Board Director
2023
High-Throughput Gene Editing Platform to Accelerate Cell Therapy Discovery, Development, and Manufacturing
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Raised $39,098,461.00 from National Institute of Allergy and Infectious Diseases.
Board Director
2023
Clinical trial site engagement platform.
Board Director
2022
Digital chemistry, manufacturing, and controls (CMC) platform.
QbDVision project to address the lack of digital maturity in pharma and biotech manufacturing.
Raised $17,000,000.00 from Hudson Park Capital, S3 Ventures, Wanxiang America Healthcare Investments Group and Northpond Ventures.
Board Director
2023
Platform biotech accelerating drug development via decentralized scientific communities
Board Observer
2021
Lab connectivity platform.
Scitara offers a cloud-based connectivity platform that transforms integration between instruments and lab informatics applications.
Raised $30,750,000.00 from Flybridge and Northpond Ventures.
Board Observer
2021
AI-enabled oncology care and practice management platform.
VieCure built an engine to turn data into knowledge and take the world’s best thinking to clinicians and patients in real time.
Raised $70,000,000.00 from Northpond Ventures.
Board Observer
2021
Ex-vivo drug response monitoring platform.
Elephas harnesses latest advances in cancer biology, multimodal microscopy, and artificial intelligence to empower clinical decision-making.
Raised $123,500,000.00 from Venture Investors, TAO Investments, State of Wisconsin Investment Board, WARF Ventures, Sands Capital Ventures, ARCH Venture Partners, Northpond Ventures and Moore Strategic Ventures.
Board Observer
2019 - 2025
Antibiotic susceptibility testing platform.
SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.
Raised $220,499,998.00 from Sands Capital Ventures, Schooner Capital, RA Capital Management and Northpond Ventures.